These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 38758628

  • 21. Stiripentol add-on therapy for drug-resistant focal epilepsy.
    Brigo F, Igwe SC, Bragazzi NL.
    Cochrane Database Syst Rev; 2020 May 26; 5(5):CD009887. PubMed ID: 32468572
    [Abstract] [Full Text] [Related]

  • 22. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
    Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M.
    CNS Drugs; 2020 Jun 26; 34(6):661-672. PubMed ID: 32350749
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome.
    Yıldız EP, Ozkan MU, Uzunhan TA, Bektaş G, Tatlı B, Aydınlı N, Çalışkan M, Özmen M.
    J Child Neurol; 2019 Jan 26; 34(1):33-37. PubMed ID: 30362398
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
    Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, Johannessen SI.
    Ther Drug Monit; 2012 Aug 26; 34(4):440-5. PubMed ID: 22777154
    [Abstract] [Full Text] [Related]

  • 26. Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety.
    Dahlin MG, Ohman I.
    Neuropediatrics; 2012 Oct 26; 43(5):264-70. PubMed ID: 22941776
    [Abstract] [Full Text] [Related]

  • 27. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S, FAiRE, DS Study Group.
    JAMA Neurol; 2020 Mar 01; 77(3):300-308. PubMed ID: 31790543
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Effectiveness and safety of rufinamide at treatment of epilepsy with complications and drug-resistant epilepsy (according to meta-analysis data)].
    Mazin PV, Sheshunov IV, Kislitsyn YV, Mazina NK.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016 Mar 01; 116(8):40-43. PubMed ID: 27635610
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic Variability of Sulthiame: The Impact of Age, Drug-Drug Interactions, and Biochemical Markers of Toxicity in Patients with Epilepsy.
    Heger K, Kjeldstadli K, Ring N, Aaberg KM, Kjeldsen SF, Burns ML, Johannessen SI, Johannessen Landmark C.
    Ther Drug Monit; 2024 Apr 01; 46(2):237-245. PubMed ID: 38158595
    [Abstract] [Full Text] [Related]

  • 32. [Therapeutic drug monitoring of stiripentol].
    Verdier MC, Tribut O, Bentué-Ferrer D.
    Therapie; 2012 Apr 01; 67(2):157-60. PubMed ID: 22850103
    [Abstract] [Full Text] [Related]

  • 33. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
    Wisniewski CS.
    Ann Pharmacother; 2010 Apr 01; 44(4):658-67. PubMed ID: 20233912
    [Abstract] [Full Text] [Related]

  • 34. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
    Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, Spalice A, Habetswallner F, Fels A, Capovilla G, Verrotti A, Mangano S, Balestri A, Curatolo P, Pascotto A.
    Seizure; 2010 Nov 01; 19(9):587-91. PubMed ID: 20888268
    [Abstract] [Full Text] [Related]

  • 35. Stiripentol add-on therapy for focal refractory epilepsy.
    Brigo F, Igwe SC, Bragazzi NL.
    Cochrane Database Syst Rev; 2018 May 10; 5(5):CD009887. PubMed ID: 29747241
    [Abstract] [Full Text] [Related]

  • 36. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
    Coppola G, Besag F, Cusmai R, Dulac O, Kluger G, Moavero R, Nabbout R, Nikanorova M, Pisani F, Verrotti A, von Stülpnagel C, Curatolo P.
    Eur J Paediatr Neurol; 2014 Nov 10; 18(6):685-90. PubMed ID: 24929673
    [Abstract] [Full Text] [Related]

  • 37. Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).
    Plosker GL.
    CNS Drugs; 2012 Nov 10; 26(11):993-1001. PubMed ID: 23018548
    [Abstract] [Full Text] [Related]

  • 38. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
    Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, Devinsky O, Chugani H, Hernandez A, Hamiwka L, Mikati MA, Valencia I, Le Guern ME, Chancharme L, de Menezes MS.
    Epilepsia; 2013 Sep 10; 54(9):1595-604. PubMed ID: 23848835
    [Abstract] [Full Text] [Related]

  • 39. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy.
    Kim SH, Lee JH, Ryu HW, Lim BC, Chae JH, Choi JE, Hwang YS, Kim KJ.
    Epileptic Disord; 2013 Mar 10; 15(1):49-54. PubMed ID: 23531645
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Tolerability of Rufinamide in Epileptic Children Younger Than 4 Years.
    Tanritanir A, Wang X, Loddenkemper T.
    J Child Neurol; 2021 Mar 10; 36(4):281-287. PubMed ID: 33231110
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.